Kirlic N

Compass Pathways, Inc. (a subsidiary of Compass Pathways plc), New York, United States.

6 papers

ArticlePsilocybin

The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysis.

Goodwin GM, Aaronson ST, Alvarez O +23

Europe PMC2026
ArticlePsilocybin

Investigational psilocybin treatment for post-traumatic stress disorder: a qualitative study of participant experience, trauma engagement, and differences from standard treatment.

Modlin NL, Williamson V, Goodwin GM +10

Europe PMC2025
ArticlePsilocybin

Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532].

Goodwin GM, Aaronson ST, Alvarez O +28

Europe PMC2026
ArticlePsilocybin

Clinical conceptualisation of PTSD in psilocybin treatment: disrupting a pre-determined and over-determined maladaptive interpretive framework.

Modlin NL, Williamson V, Maggio C +4

Europe PMC2025
ArticlePsilocybin

The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.

Goodwin GM, Aaronson ST, Alvarez O +28

Europe PMC2025
ArticlePsilocybin

Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation.

Modlin NL, Miller TM, Rucker JJ +4

Europe PMC2023